HC Wainwright Analysts Increase Earnings Estimates for ELVN

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – HC Wainwright increased their Q2 2026 EPS estimates for shares of Enliven Therapeutics in a note issued to investors on Monday, May 11th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.41) per share for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $56.00 target price on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($1.77) EPS.

Several other analysts have also recently weighed in on the company. The Goldman Sachs Group lifted their price target on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Mizuho upped their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Guggenheim assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday. They set a “buy” rating and a $80.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.17.

Enliven Therapeutics Stock Performance

NASDAQ ELVN opened at $42.30 on Wednesday. The firm has a 50-day moving average of $37.73 and a 200-day moving average of $27.75. The stock has a market cap of $2.58 billion, a PE ratio of -25.33 and a beta of 0.32. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06.

Insider Activity

In other news, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. This represents a 16.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director directly owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their position. The SEC filing for this sale provides additional information. 25.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently bought and sold shares of ELVN. Dimensional Fund Advisors LP increased its stake in shares of Enliven Therapeutics by 70.9% in the first quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock valued at $26,714,000 after buying an additional 282,822 shares during the period. KBC Group NV bought a new position in Enliven Therapeutics during the 1st quarter worth approximately $38,000. Jennison Associates LLC bought a new position in Enliven Therapeutics during the 1st quarter worth approximately $12,120,000. Bank of New York Mellon Corp lifted its position in shares of Enliven Therapeutics by 8.6% in the 1st quarter. Bank of New York Mellon Corp now owns 120,057 shares of the company’s stock worth $4,706,000 after purchasing an additional 9,488 shares during the period. Finally, Candriam S.C.A. lifted its position in shares of Enliven Therapeutics by 31.1% in the 1st quarter. Candriam S.C.A. now owns 594,079 shares of the company’s stock worth $23,288,000 after purchasing an additional 141,060 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.